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Abstract. 
 
The cause of Huntington’s disease (HD) is a
pathological expansion of the polyglutamine domain
 
within the NH
 
2
 
-terminal region of huntingtin. Neuro-
nal intranuclear inclusions and cytoplasmic aggregates
composed of the mutant huntingtin within certain neu-
ronal populations are a characteristic hallmark of HD.
Because in vitro expanded polyglutamine repeats are
glutaminyl-donor substrates of tissue transglutaminase
(tTG), it has been hypothesized that tTG may contribute
to the formation of these aggregates in HD. Therefore, it
is of fundamental importance to establish whether tTG
 
plays a signiﬁcant role in the formation of mutant
huntingtin aggregates in the cell. Human neuroblas-
toma SH-SY5Y cells were stably transfected with
 
truncated NH
 
2
 
-terminal huntingtin constructs containing
 
18 (wild type) or 82 (mutant) glutamines. In the cells ex-
pressing the mutant truncated huntingtin construct,
numerous SDS-resistant aggregates were present in
the cytoplasm and nucleus. Even though numerous
 
aggregates were present in the mutant huntingtin-
expressing cells, tTG did not coprecipitate with mutant
truncated huntingtin. Further, tTG was totally excluded
from the aggregates, and signiﬁcantly increasing tTG
expression had no effect on the number of aggregates
or their intracellular localization (cytoplasm or nucleus).
 
When a YFP-tagged mutant truncated huntingtin
construct was transiently transfected into cells that
express no detectable tTG due to stable transfection
with a tTG antisense construct, there was extensive ag-
gregate formation. These ﬁndings clearly demonstrate
that tTG is not required for aggregate formation, and
does not facilitate the process of aggregate formation.
Therefore, in HD, as well as in other polyglutamine
diseases, tTG is unlikely to play a role in the formation
of aggregates.
Key words: Huntington’s disease • inclusions • poly-
glutamine • polar zipper • isopeptide bond
 
Introduction
 
Huntington’s disease (HD)
 
1
 
 is an autosomal-dominant
neurodegenerative disorder caused by pathological expan-
sion of polyglutamine repeats in the NH
 
2
 
-terminal region
of a 350-kD protein of unknown function called hunting-
tin (The Huntington’s Disease Collaborative Research
Group, 1993). Although mutant huntingtin is a fundamental
cause of HD, the specific molecular mechanisms responsible
for the selective neuronal degeneration remain to be eluci-
dated. A pathological hallmark of HD brain is the presence
of cytoplasmic and nuclear aggregates in specific neuronal
 
populations that contain the NH
 
2
 
-terminal region of mutant
huntingtin (DiFiglia et al., 1997). Further, protein aggre-
gates have been reported in the brains of transgenic HD
mouse models, as well as in transfected cell models of HD
(Davies et al., 1997; Saudou et al., 1998; Persichetti et al.,
1999; Yamamoto et al., 2000). Although it is clear that cy-
toplasmic and nuclear inclusions occur in HD, and in other
polyglutamine diseases, the role of the inclusions in the
pathogenesis of the disease remains inconclusive. Indeed,
there have been reports indicating that aggregates may be
beneficial (Klement et al., 1998; Saudou et al., 1998;
Gutekunst et al., 1999), while others studies have con-
cluded that the aggregates are likely to be toxic (Hackam
et al., 1998; Hackam et al., 1999; Li, 2000).
Two mechanisms have been proposed to explain how ex-
panded polyglutamine domains form insoluble aggregates.
It has been hypothesized that the expanded polyglutamine
repeats may interact with each other through a polar zipper
and thus contribute to aggregate formation (Perutz et al.,
 
1994). Further, it has been hypothesized that tissue trans-
glutaminase (tTG), perhaps in conjunction with the polar
zipper mechanism, may be a contributing factor in the
formation of these aggregates (Cooper et al., 1997, 1999;
Kahlem et al., 1996, 1998). Because it has been proposed
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that tTG may be a potential therapeutic target in the treat-
ment of polyglutamine diseases (Igarashi et al., 1998), it is
of critical importance to determine the contribution of
tTG to the formation of inclusions.
The transglutaminases are a family of calcium-depen-
dent enzymes that catalyze the formation of 
 
e
 
-(
 
g
 
-glu-
tamyl)lysine isopeptide bonds between substrate proteins,
rendering the resulting cross-linked protein complexes
insoluble (Folk, 1983; Lorand and Conrad, 1984; Green-
berg et al., 1991). Transglutaminases also catalyze the in-
corporation of polyamines into substrate proteins (Lorand
and Conrad, 1984; Greenberg et al., 1991). Because the
polypeptide-bound glutamine is the primary determining
factor for a transglutaminase-catalyzed reaction, it has
been hypothesized that increasing the number of glu-
tamines in a protein beyond a certain threshold may result
in the protein becoming a transglutaminase substrate
(Green, 1993). tTG is found within neurons (Miller and
Anderton, 1986; Appelt et al., 1996; Lesort et al., 1999)
and is increased in specific areas affected in HD brain
(Karpuj et al., 1999; Lesort et al., 1999). Further, the in-
crease in tTG expression in HD brain occurred within
neurons (Lesort et al., 1999). Previously, it had been
shown that tTG levels in SH-SY5Y cells are significantly
increased by treatment with retinoic acid, and further tTG
can be activated by increasing intracellular calcium levels
(Zhang et al., 1998). Even though it has been demon-
strated that polyglutamine repeat domains (Kahlem et al.,
1996; Cooper et al., 1997) and mutant huntingtin (Kahlem
et al., 1998) are substrates for tTG in vitro, it has not yet
been shown that huntingtin interacts with or is modified
by tTG in situ. To determine the potential role of tTG in
aggregate formation, SH-SY5Y cell lines stably expressing
mutant or wild-type truncated NH
 
2
 
-terminal huntingtin
constructs were established. Using these cells, we demon-
strate that tTG and the mutant truncated huntingtin do
not interact, and further huntingtin is not modified by tTG
in situ. Moreover, immunocytochemical analysis revealed
that tTG was totally excluded from the aggregates that
form in the cells expressing the mutant huntingtin con-
struct. Finally, transient transfection of the YFP-tagged
mutant huntingtin construct into cells that do not express
detectable levels of tTG due to stable transfection with an
antisense tTG construct, resulted in significant aggregate
formation. In addition, the formation of mutant huntingtin
aggregates was equivalent in tTG antisense cells and in
cells stably transfected with vector only. These data clearly
demonstrate that tTG is unlikely to be a contributing fac-
tor to the formation of aggregates in HD brain.
 
Materials and Methods
 
Construction of Expression Plasmids
 
Expression constructs of truncated huntingtin with 63 amino acids,
pcDNA3.1-N63-18/82Q-Myc/His, were created by subcloning a fragment of
the huntingtin cDNA (bp 314–503) generated by PCR and included BamHI
and XhoI restriction sites. The 189-bp product of interest was digested with
BamHI and XhoI, and then subcloned into pcDNA3.1-/His A vector (Coo-
per et al., 1998). The BamHI–XhoI huntingtin cDNA fragments were also
subcloned into the Amersham Pharmacia Biotech and XhoI sites of the
pECFP-N1 vector (CLONTECH Laboratories, Inc.) (N-Q18) (pECFP-N1-
18Q) or into the NheI and XhoI sites of the pEYFP-N1 vector (CLON-
TECH Laboratories, Inc.) (N-Q82) (pEYFP-N1-82Q). The BamHI and
NheI restriction sites were filled in with T4 DNA polymerase before liga-
tion. All DNA constructs were verified by automated sequencing.
 
Cell Culture and Generation of Stable Cell Lines
 
Human neuroblastoma SH-SY5Y cells were transfected by electropora-
tion (Gene Pulser II; Bio-Rad Laboratories) according to the supplier’s
instructions. SH-SY5Y cells stably expressing pcDNA3.1 vector alone,
N-Q82 (wild-type truncated huntingtin) or N-Q18 (mutant truncated hun-
tingtin) were selected based on their resistance to G418, subcloned, and
maintained on Corning dishes in RPMI 1640 medium supplemented with
20 mM glutamine, 10 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 5% fetal
clone II serum, 10% horse serum, and 100 
 
m
 
g/ml G418 (GIBCO BRL). To
differentiate the cells, the cells were grown in medium containing 1% fetal
clone II serum, 5% horse serum, and 20 
 
m
 
M retinoic acid for 5 d. Previous
studies have shown that treatment of SH-SY5Y cells with retinoic acid re-
sults in a significant increase in tTG expression (Zhang et al., 1998). Ex-
cept where indicated, all studies were carried out on cells that were
treated with retinoic acid and therefore express high levels of tTG (Zhang
et al., 1998). All experiments were carried out on sub-confluent cultures.
 
Cell Viability Assay
 
To determine whether truncated mutant huntingtin decreases basal cell
viability, LDH release was measured in the cell lines (Decker and Loh-
mann-Matthes, 1988; Davis et al., 1997). There was no significant difference
among groups, indicating no loss of cell viability due to the expression of
the mutant huntingtin (data not shown). Further, there was no evidence of
increased apoptosis in the mutant huntingtin-expressing cells as deter-
mined by the presence of condensed chromatin as detected by Hoechst
staining (data not shown).
 
Antibodies
 
A rabbit polyclonal huntingtin antibody was prepared using a synthetic
peptide composed of the first 17 amino acids of huntingtin protein and af-
finity purified using the antigen (a gift from Dr. P. Detloff, University of
Alabama at Birmingham, Birmingham, AL) (Lin et al., 2001). This hun-
tingtin antibody was made and purified by Research Genetics. The anti-
gen and reactivity of this NH
 
2
 
-terminal huntingtin antibody are identical
to the NH
 
2
 
-terminal huntingtin antibody described by Sawa et al. (1999).
Mouse monoclonal antibodies to C-myc (Zymed Laboratories), tTG
(TG100 and CUB7402) (Neomarkers), Hsp70 (StressGen Biotechnolo-
gies), and ubiquitin (Zymed Laboratories) were also used in this study.
 
Immunoblotting
 
To evaluate the expression levels of tTG and the huntingtin proteins in
naive and differentiated cells, extracts from cells were prepared and quan-
titatively immunoblotted. Cells were harvested in cold PBS, collected by
centrifugation, resuspended in a homogenizing buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.1 mM phenylmethyl-
sulfonyl fluoride, and a 10 
 
m
 
g/ml concentration each of aprotinin, leupep-
tin, and pepstatin), and sonicated on ice. Protein concentrations of the ho-
mogenates were determined using the BCA method (Pierce Chemical
Co.) and diluted to a final concentration of 2 mg/ml with 2
 
3
 
 reducing stop
buffer (0.25 M Tris-HCl, pH 6.8, 5 mM EDTA, 5 mM EGTA, 25 mM
dithiothreitol, 2% SDS, 10% glycerol, and bromophenol blue as the track-
ing dye). Samples (30 
 
m
 
g of protein) were resolved on 4–20% gradient
SDS-polyacrylamide gels, and transferred to nitrocellulose. Blots were
blocked in 5% nonfat dry milk in TBST (20 mM Tris-HCl, pH 7.6, 137
mM NaCl, 0.05% Tween 20) for 1 h at room temperature. The blots were
then incubated with the anti–tTG monoclonal antibody TG100 (1:750;
Neomarkers) or with a polyclonal huntingtin antibody (1:20,000) in the
same buffer overnight at 4
 
8
 
C. The membranes were then washed three
times with TBST and incubated with HRP-conjugated goat anti–mouse
IgG (1:2,000) for tTG, or with HRP-conjugated goat anti–rabbit IgG
(1:2,000) for the polyclonal huntingtin antibody for 2 h at room tempera-
ture. The membranes were rinsed three times for 30 min with TBST, fol-
lowed by four quick rinses with distilled water, and developed with the en-
hanced chemiluminescence method (Amersham Pharmacia Biotech).
 
Coimmunoprecipitation
 
Cell lysates were prepared in homogenizing buffer and samples containing
200 
 
m
 
g of protein were precleared for 1 h at 4
 
8
 
C with protein A-Sepharose
(Amersham Pharmacia Biotech) before immunoprecipitation of hunting-
tin. Precleared samples were immunoprecipitated overnight at 4
 
8
 
C with
the polyclonal NH
 
2
 
-terminal huntingtin antibody. To control for nonspe-
cific binding, some samples were immunoprecipitated with nonimmune
rabbit IgG. Protein A–Sepharose was added, and the incubation contin- 
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ued for 3 h at 4
 
8
 
C. The precipitates were washed three times with 1.0%
NP-40, 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA, 0.1 mM
phenylmethylsulfonyl fluoride, and a 10 
 
m
 
g/ml concentration each of apro-
tinin, leupeptin, and pepstatin, 50 
 
m
 
l of 1
 
3
 
 reducing stop buffer was added
to each sample and the samples were placed in a boiling water bath for 15
min before SDS-PAGE and immunoblotting. Blots were probed with the
monoclonal tTG antibody TG100, and then stripped by incubation in 100
mM 
 
b
 
-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 7.6, at 50
 
8
 
C for
30 min with agitation, rinsed thoroughly with TBST, blocked with 5%
milk/TBST overnight, and reprobed with the monoclonal C-myc antibody.
 
Immunocytochemistry
 
Cells were seeded on poly-
 
D
 
-lysine–coated cover slips in 24-well plates. 24 h
later, cells were fixed in 90% methanol, 50 mM EGTA, pH 6.0, for 5 min at
 
2
 
20
 
8
 
C (Melan and Sluder, 1992), incubated for 10 min with 0.2% Triton
X-100 in PBS, and rinsed three times with PBS, before incubation with 5%
bovine serum albumin in PBS for 90 min to reduce the background. Cells
were then incubated at room temperature for 90 min with the polyclonal
NH
 
2
 
-terminal huntingtin antibody (1:20,000) in 5% BSA/PBS. Cells were
then rinsed three times with PBS, incubated for 60 min at room temperature
with FITC-conjugated anti–rabbit IgG (1:200) in 5% BSA/PBS. For colocal-
ization studies, cells were treated with 20 
 
m
 
M retinoic acid for 5 d before fix-
ation and permeabilization. Cells were then incubated at room temperature
for 90 min with the polyclonal NH
 
2
 
-terminal huntingtin antibody (1:20,000)
and the monoclonal tTG antibody CUB7402 (1:20), or the monoclonal
Hsp70 antibody (1:200), or the monoclonal ubiquitin antibody (1:200). Cells
were then rinsed three times with PBS and incubated for 60 min at room
temperature with FITC-conjugated anti–rabbit IgG (1:200) and Texas red–
conjugated anti–mouse IgG (1:100). Cells were then rinsed with PBS and in-
cubated with 5 
 
m
 
g/ml Hoescht for 30 min at room temperature. Coverslips
were then washed extensively in PBS and mounted. Cells were viewed using
confocal microscopy and images were acquired by sequential scanning at the
appropriate wavelengths. The digitally stored images were combined and
displayed with the accompanying software and Adobe Photoshop 4.0.
 
Expression of C/YFP-tagged Huntingtin Constructs in 
Antisense tTG Cells
 
To essentially abolish tTG expression, SH-SY5Y cells were stably trans-
fected with an antisense tTG construct as described previously (Tucholski
et al., 2001). There is no detectable tTG expression or transglutaminase
activity in these antisense tTG cells (Tucholski et al., 2001).
 
The pcDNA and antisense tTG cells were plated onto poly-
 
D
 
-lysine–
coated coverslips in six-well plates 24 h before transfection with pECFP-N1-
18Q or pEYFP-N1-82Q using FUGENE™6, according to the manu-
facturer’s protocol. As a control, pcDNA and antisense tTG cells were
transfected with pECFP-N1 or pEYFP-N1. At 24 and 48 h after transfec-
tion, the cells were washed with PBS and subsequently fixed for 30 min at
room temperature in 70 mM Pipes, pH 6.9, 1 mM MgCl
 
2
 
, 1 mM EGTA, 2%
paraformaldehyde, 0.2% glutaraldehyde, 30% (vol/vol) glycerol. Cells were
washed with PBS and incubated with 5 
 
m
 
g/ml Hoeschst for 30 min at room
temperature, rinsed three times with 0.1
 
3
 
 PBS, and extensively with water
before mounting the coverslips. After mounting the coverslips, the cells
were viewed using confocal microscopy. All images were captured with the
accompanying software and displayed using Adobe Photoshop 4.0.
 
In Situ TG Activity Assay and Detection of
tTG-modified Proteins
 
Cells were labeled with 2 mM 5-(biotinamido)pentylamine (Pierce Chem-
ical Co.), a biotinylated polyamine, for 45 min. To increase intracellular
levels of calcium and therefore activate tTG, 2 nM maitotoxin was added
to the cells for 20 min. Transglutaminase activity was quantified by
measuring the transglutaminase-dependent incorporation of 5-(biotin-
amido)pentylamine into proteins by a microplate assay as described by
Zhang et al. (1998).
To determine whether huntingtin or huntingtin-associated proteins
were modified by tTG, cells were labeled with 2 mM 5-(biotinamido)pen-
tylamine and treated with maitotoxin as described above. Clarified cell ly-
sates were prepared and samples containing 200 
 
m
 
g of protein were immu-
noprecipitated with the polyclonal NH
 
2
 
-terminal huntingtin antibody.
Protein A-Sepharose was added, and the incubation continued for 3 h at
4
 
8
 
C. After the precipitates were washed three times, 40 
 
m
 
l of 1
 
3
 
 reducing
stop buffer was added to each sample and the samples boiled before SDS-
PAGE and immunoblotting. Blots were probed with the monoclonal myc
antibody (1:2,000), developed with ECL, and then stripped and reprobed
with HRP-conjugated neutravidin (1:2,000).
 
Results
 
To demonstrate the specificity of the polyclonal NH
 
2
 
-ter-
minal huntingtin antibody, cell extracts from the vector
control cells were immunoblotted. The immunoblot in
Fig. 1 A demonstrates that the antibody recognizes en-
Figure 1. (A) Representative immunoblot of endogenous huntingtin in vector-transfected SH-SY5Y cells probed with the polyclonal
NH2-terminal huntingtin antibody. (B) Vector-transfected and N-Q18 cells stained with the polyclonal NH2-terminal huntingtin anti-
body. In the vector-transfected cells, immunoreactivity is extremely low in comparison with the strong signal in the N-Q18 cells. 
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dogenous huntingtin. However, the levels of endogenous
huntingtin in these cells is low, and this immunoblot had
to be exposed a relatively long time to bring up the signal.
In Fig. 1 B immunocytochemical analyses with the poly-
clonal NH
 
2
 
-terminal huntingtin antibody in vector-trans-
fected and N-Q18 cells are shown. These data demon-
strate that immunoreactivity is extremely low in the
vector cells; however, in the N-Q18 cells, expression is
significantly elevated.
To determine the putative role of tTG in aggregate for-
mation, SH-SY5Y cells stably transfected with the trun-
cated NH
 
2
 
-terminal huntingtin constructs N-Q18 (wild-
type truncated huntingtin) or N-Q82 (mutant truncated
huntingtin) were established. Immunoblot analysis re-
vealed that in the N-Q18 cells there was a huntingtin im-
munoreactive band, as expected, at 
 
z
 
14 kD (Fig. 2). In the
N-Q82 cells, huntingtin immunoreactive bands were ob-
served at 
 
z
 
23 and 55 kD. The 55-kD band is likely be a
complex containing the truncated mutant huntingtin. As
expected, retinoic acid treatment increased the expression
of tTG without effecting the expression of the transfected
protein (Fig. 2). Further, treatment with retinoic acid had
no effect on cell viability in either the N-Q18 or the N-Q82
cells (data not shown).
Figure 2. Representative immunoblots of the expression of trun-
cated NH2-terminal huntingtin (top) and tTG (bottom) in SH-SY5Y
cells stably expressing truncated NH2-terminal huntingtin con-
structs, N-Q18 or N-Q82. Cells were incubated in the absence
(2) or presence (1) of 20 mM retinoic acid (RA) for 5 d before
immunoblotting for huntingtin or tTG. N-Q18 cells displayed a
major huntingtin immunoreactive band at z14 kD and in N-Q82
cells, two truncated NH2-terminal huntingtin immunoreactive
bands were detected at z23 and 55 kD. The 55-kD band is likely
to be a complex containing the truncated NH2-terminal huntingtin.
Treatment of the cells with RA resulted in a significant increase in
tTG levels, but did not alter the expression or levels of the
truncated NH2-terminal huntingtin protein.
Figure 3. Huntingtin immunostaining in cells stably transfected with N-Q18 or N-Q82. Huntingtin localization was detected with an
NH2-terminal polyclonal huntingtin antibody. In the N-Q18 cells, huntingtin immunostaining was diffuse throughout the cytoplasm (a).
In contrast, in the N-Q82 cells, huntingtin formed large aggregates in the cytoplasm (b and c) and also in the nucleus (b and d). Note
also the presence of diffuse huntingtin immunoreactivity in the nucleus of N-Q82 cells (d). 
Chun et al. 
 
Tissue Transglutaminase Is Not Essential for Aggregate Formation
 
29
 
To evaluate the intracellular distribution of N-Q18 and
N-Q82, immunocytochemical analyses were carried out
using the polyclonal NH
 
2
 
-terminal huntingtin antibody. In
N-Q18 cells huntingtin immunoreactivity was diffuse
through the cytoplasm in all the cells (Fig. 3 a). In the
N-Q82 cells, diffuse huntingtin immunoreactivity was also
observed; however, in 
 
z
 
13% of the cells cytoplasmic and/
or nuclear aggregates were observed (Fig. 3, b–d). There
was also evidence of diffuse huntingtin staining in the nu-
cleus of N-Q82 cells (Fig. 3 d). Identical results were ob-
tained with the monoclonal antibody to c-myc (data not
shown).
To further evaluate the inclusions formed by N-Q82,
cells were costained for huntingtin and ubiquitin or Hsp70,
as inclusions in models of HD and other polyglutamine
diseases are usually ubiquitinated and often reactive with
antibodies to heat shock proteins (Davies et al., 1997; Sau-
dou et al., 1998; Wyttenbach et al., 2000). The majority of
the aggregates were immunopositive for both ubiquitin
and hsp70 (Fig. 4). Interestingly, both the huntingtin and
ubiquitin antibodies stained the peripheral areas of the in-
clusions, while the Hsp70 antibody stained the entire in-
clusion (Fig. 4). The reason for the peripheral staining pat-
tern of the aggregates with the NH
 
2
 
-terminal huntingtin
and ubiquitin antibodies is unknown, but may be due to
the organization of the inclusion that results in “masking”
of the NH
 
2
 
-terminal portion of the huntingtin at the center
of the inclusion. In addition, when N-Q82 cells were co-
stained for huntingtin and C-myc, there was complete
overlap of the immunostaining, clearly demonstrating that
the truncated huntingtin is a primary constituent of the ag-
gregates (Fig. 5).
To determine whether tTG and highly truncated hun-
tingtin interact, coimmunoprecipitation assays were car-
ried out. N-Q18 huntingtin coprecipitated with tTG; how-
ever, this interaction was not increased when tTG was
Figure 4. Aggregates of N-Q82 are ubiquitinated and colocalize with Hsp70. Cells were double labeled with the polyclonal huntingtin
antibody (green) and with the monoclonal ubiquitin or Hsp70 antibody (red), and nuclei were counterstained with Hoechst (blue). Ag-
gregates of N-Q82 were ubiquitinated and ubiquitin immunoreactivity colocalized in the peripheral areas of the inclusion (a–c). Hsp70
immunoreactivity colocalized with the aggregates and stained the entire inclusion (d–f).
Figure 5. Colocalization of hun-
tingtin and C-myc immunoreac-
tivity in N-Q82 cells. N-Q82 cells
were double labeled with the
polyclonal huntingtin antibody
(green) and with the monoclonal
C-myc antibody (red). Nu-
clei were counterstained with
Hoechst (blue). Huntingtin and
C-myc immunoreactivity showed
complete overlap, especially at
the levels of the aggregates. 
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activated (Fig. 6 A). tTG is associating with the N-Q18, as
when endogenous full-length huntingtin was immunopre-
cipitated from the parental SH-SY5Y cells line, tTG did
not coimmunoprecipitate with the huntingtin (data not
shown). In contrast, N-Q82 huntingtin only showed a very
weak interaction with tTG (Fig. 6 A). SDS-resistant mate-
rial that contained the N-Q82 huntingtin was detected at
the top of the gel, indicating that insoluble aggregates had
formed. When the N-Q82 or N-Q18 cells were immuno-
precipitated with nonimmune rabbit IgG, no huntingtin
precipitated (Fig. 6 B). To determine whether tTG colo-
calized with the highly truncated huntingtin, costaining
was carried out with the huntingtin and tTG antibodies. In
the N-Q18 cells, both huntingtin and tTG immunoreactiv-
ity were diffuse through the cytoplasm (Fig. 7, a–c). In the
N-Q82 cells, there was also no specific colocalization of
tTG and huntingtin and, further, tTG immunoreactivity
was completely excluded from the aggregates (Fig. 7, d–i).
In addition, the number of N-Q82 cells with aggregates
was similar in control conditions and after increased tTG
expression due to retinoic acid treatment (Fig. 8). To de-
termine whether tTG modifies highly truncated huntingtin
or associated proteins, cells were prelabeled with 5-(bio-
tinamido)pentylamine, incubated in the absence or pres-
ence of maitotoxin, and immunoprecipitated with the
polyclonal huntingtin antibody, probed with a C-myc anti-
body, and then stripped and reprobed with neutravidin-
HRP. The results of these experiments demonstrated that
neither truncated huntingtin nor any huntingtin-associated
proteins were modified by tTG (data not shown).
To confirm that tTG does not play a role in the forma-
tion of mutant huntingtin inclusions, pEYFP-N1-82Q or
pCYFP-N1-18Q were transiently transfected into cells sta-
 
bly transfected with vector (pcDNA3.1) only or into cells
stably transfected with an antisense tTG construct. In the
antisense tTG cells, tTG is undetectable and there is no
measurable transglutaminase activity (Tucholski et al.,
2001). As expected, transient transfection of pCYFP-N1-
18Q into either the pcDNA or antisense tTG cells did
not result in any aggregate formation (data not shown).
In contrast, transient transfection of pEYFP-N1-82Q
resulted in abundant aggregate formation in both the
pcDNA and antisense cells (Fig. 9). These studies clearly
demonstrate that it is unlikely that tTG plays a role in the
formation of inclusions in HD brain.
 
Discussion
 
The hypothesis that tTG contributes to the etiology of HD
was first proposed by Green (1993) before the identifica-
tion of huntingtin aggregates in HD brain. With the dis-
covery of intranuclear and cytoplasmic inclusions of mu-
tant huntingtin in HD brain (DiFiglia et al., 1997) and in
transgenic mouse models for HD (Davies et al., 1997), it
was further hypothesized that tTG may facilitate the for-
mation of these aggregates by selectively cross linking mu-
tant huntingtin (Cooper et al., 1999). Indeed, it has even
been suggested that tTG may be a potential therapeutic
target in the treatment of polyglutamine diseases (Igarashi
et al., 1998). Additionally, tTG levels and transglutami-
nase activity are significantly increased in HD brain (Kar-
puj et al., 1999; Lesort et al., 1999) in a grade- and region-
dependent manner, and there is a significant increase in
the tTG immunoreactivity in specific neuronal popula-
tions in HD brain (Lesort et al., 1999). Although these
findings are intriguing, there has been no direct demon-
Figure 6. (A) In situ association between truncated NH2-terminal huntingtin
and tTG. Cells stably expressing N-Q18 or N-Q82 were treated with 20 mM
retinoic acid for 5 d and incubated in the absence (2) or presence (1) of MTX.
Huntingtin was immunoprecipitated with the polyclonal huntingtin antibody
and immunoblotted with a monoclonal tTG antibody (left). Immunoblots were
stripped and reprobed with a monoclonal C-myc antibody (right). These results revealed that N-Q18 and tTG interact; however, there is
only a very weak association between N-Q82 and tTG. Further, activation of tTG did not have any effect on the association of tTG and
N-Q18. The bands at the top of the gel in the C-myc blot of the N-Q82 lane confirm the presence of SDS-insoluble huntingtin aggre-
gates. The immunoreactive bands in the C-myc blot of N-Q18 cells at z55 kD is IgG, as the goat anti–mouse secondary antibody
weakly recognizes the rabbit IgG used in the immunoprecipitation. (B) Cells stably expressing N-Q18 or N-Q82 were treated with 20
mM retinoic acid for 5 d, incubated in the absence (2) or presence (1) of MTX, immunoprecipitated with nonimmune rabbit IgG, and
probed with the C-myc antibody. These data demonstrate that the precipitation of N-Q18 and N-Q82 is selective, as there was no
C-myc reactivity present when the nonimmune IgG was used. 
Chun et al. 
 
Tissue Transglutaminase Is Not Essential for Aggregate Formation
 
31
 
stration that tTG is involved in the formation of aggre-
gates in HD or other polyglutamine diseases. Therefore,
the goals of this study were to determine whether or not
tTG and huntingtin interact in situ, and whether tTG facil-
itates the formation of mutant huntingtin aggregates.
It has been well documented that in vitro polyglutamine
constructs and mutant huntingtin are substrates for tTG
(Kahlem et al., 1996, 1998; Cooper et al., 1997). However,
the ability of tTG to modify mutant huntingtin in situ has
not been demonstrated, and the putative contribution of
tTG in the formation of polyglutamine aggregates is still
controversial. It was reported that transglutaminase inhib-
itors suppressed aggregate formation and apoptosis in
cells expressing truncated DRPLA protein with an ex-
panded polyglutamine domain (Igarashi et al., 1998).
These findings need to be interpreted with some caution
as both transglutaminase inhibitors used in this study can
also inhibit other enzymes (e.g., caspases), and in some
cases the transglutaminase inhibitors reduced apoptotic
cell death, but were ineffective in blocking the formation
of aggregates (Lorand, 1998). In another study, tTG over-
expression was reported to increase the aggregate forma-
tion of synthetic fusion proteins containing 36 or 43
glutamines. However, the percent increase in aggregate
formation induced by tTG overexpression was only 
 
z
 
10–
15% (de Cristofaro et al., 1999). These authors also pre-
sented data that cystamine, a transglutaminase inhibitor,
at relatively high concentrations (0.25 and 0.50 mM) re-
duced aggregate formation (de Cristofaro et al., 1999). In
another study, the same inhibitor (0.20 mM) had no effect
in mutant huntingtin aggregate formation, and, when the
inhibitor was used at higher concentrations (0.5 mM), it
was cytotoxic (Kim et al., 1999). These findings indicate
the need for further investigations before a reasonable
case can be made for the involvement of tTG in the etiol-
ogy of HD.
In the present study, we used human neuroblastoma SH-
SY5Y cells stably transfected with wild-type and mutant
truncated huntingtin to investigate the role of tTG in hun-
tingtin modification and aggregate formation. SH-SY5Y
Figure 7. Truncated NH2-terminal huntingtin and tTG do not colocalize. Cells were double labeled with the polyclonal huntingtin antibody
(green) and with the monoclonal tTG antibody CUB7402 (red); nuclei were counterstained with Hoechst (blue). In cells stably expressing
N-Q18, huntingtin (a) and tTG immunoreactivities (b) were diffuse throughout the cytoplasm and did not show specific colocalization (c).
In contrast, cells stably expressing N-Q82 showed large huntingtin immunoreactive aggregates in the cytoplasm (d and g) and in the nu-
cleus (g). In these cells, tTG immunoreactivity was also diffuse throughout the cytoplasm and, remarkably, appeared completely excluded
from the huntingtin aggregates (e, f, h, and i). These results demonstrate that the huntingtin aggregates and tTG do not colocalize. 
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cells are an excellent model system for these studies be-
cause they have neuronal-like features (Preis et al., 1988;
Pahlman et al., 1990; Jalava et al., 1992), and tTG expres-
sion is robustly upregulated in response to retinoic acid
(Zhang et al., 1998). Therefore, alterations in huntingtin
can be evaluated in conditions when tTG levels are low,
and also when the levels and activity of tTG are elevated.
In these cells, N-Q82 did not increase cell death under
basal conditions. However, it should be noted that overex-
pression of N-Q82 does sensitize the cells to apoptotic
stressors (Chun, W., M. Lesort, and G.V.W. Johnson, un-
published observations, manuscript in preparation). This is
in agreement with a previous study reporting that transient
transfection of the N-Q82 construct into neuroblastoma
N2a cells resulted in aggregate formation and increased
sensitivity to staurosporine-induced apoptosis; however,
no changes in cell viability under basal conditions were re-
ported (Cooper et al., 1998). Similar findings were re-
ported when mutant truncated huntingtin constructs were
transiently transfected into 293T cells; there was significant
aggregate formation and no changes in viability under
basal conditions, while the presence of the truncated hun-
tingtin constructs sensitized cells to the apoptotic stimuli
(Hackam et al., 1998).
In the SH-SY5Y cells stably overexpressing N-Q82, tTG
associated with the wild-type truncated huntingtin; how-
ever, this association was not affected by the activity state
of tTG. In addition, there was no selective association be-
 
tween tTG and the mutant truncated huntingtin. In all
cases, no in situ modification of huntingtin tTG was ob-
served. This demonstrates that although huntingtin is an in
vitro substrate of tTG (Kahlem et al., 1998), it is unlikely
to be modified by tTG in vivo. Furthermore, we found that
tTG was totally excluded from the insoluble huntingtin ag-
gregates in the N-Q82 cells, although other proteins such
as Hsp70 showed a strong colocalization with huntingtin at
the level of the aggregates. In addition, the number and
size of the aggregates in the N-Q82 cells expressing either
low or high levels (due to retinoic acid treatment) of tTG
were not significantly different. These findings demon-
strate that it is unlikely that tTG plays a role in aggregate
formation in HD brain. In addition, when pEYFP-N1-82Q
was transiently transfected into cells that had been stably
transfected with antisense tTG, and therefore express un-
detectable levels of the protein, insoluble aggregates were
still formed. Further, tTG is virtually undetectable in
mouse (C57BL) brain by immunoblot analysis (Lesort, M.,
unpublished observations), although inclusions are usually
found in the brains of mouse models of HD (Davies et al.,
1997; Schilling et al., 1999; Wheeler et al., 2000). Indeed,
given the fact that the cross-linking and polyamination re-
actions catalyzed by tTG are competing reactions (Lorand
and Conrad, 1984; Greenberg et al., 1991), and the fact
that the levels of polyamines in the brain are in the milli-
molar range (Morrison et al., 1995), it seems unlikely that
tTG catalyzes cross-linking reactions within the cells.
Therefore, another mechanism, such as the formation of
 
b
 
-sheets via the glutamine repeats acting as polar zippers
(Perutz et al., 1994; Stott et al., 1995), is more likely to be
responsible for the formation of huntingtin aggregates
in HD brain. In vitro, polyglutamine constructs form
 
b
 
-sheets that are held together by hydrogen bonds (Perutz
et al., 1994; Stott et al., 1995; Scherzinger et al., 1997). Congo
red selectively stains 
 
b
 
-sheet structure, and aggregates
from HD brain (Huang et al., 1998), as well as aggregates
Figure 8. The frequency of N-Q82 aggregates is not effected by
tTG overexpression. Cells expressing N-Q82 were incubated in
the absence or presence of 20 mM retinoic acid (RA) for 2 or 5 d.
tTG expression levels were increased in a time-dependent man-
ner (A). Treatment of the cells with RA for time periods .5 d
did not increase tTG expression further (data not shown) (Zhang
et al., 1998). The frequency of cells with aggregates was quanti-
fied in the different conditions. Approximately 13% of the cells
formed aggregates in all cells regardless of the tTG expression
level. There were no significant differences in the frequency of
aggregates in either the cytoplasm or nucleus of cells expressing
the different levels of tTG (B). Data represent three independent
experiments; 600–1,400 cells were counted for each experiment.
The data are expressed as mean% 6 SEM.
Figure 9. N-Q82 forms aggregates in the absence of tTG. pEYFP-
N1-82Q was transiently transfected into cells stably transfected with
vector only (pcDNA3.1) (a and b) or into cells stably transfected
with an antisense tTG construct (c and d). Transient transfection of
pEYFP-N1-82Q resulted in equivalent aggregate formation in both
the pcDNA (a and b) and antisense tTG cells (c and d). 
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formed from mutant huntingtin in vitro (Scherzinger et al.,
1997), stain with Congo red. These data suggest that hy-
drogen bonds between the side chain amides of glutamine
and the amides of the polypeptide backbone may be the
essential process in huntingtin aggregate formation in HD
(Perutz, 1994; Perutz et al., 1994).
It should be noted that the appearance of the aggregates
in the cells stably expressing N-Q82 compared with those
in which the N-Q82 construct was transiently transfected
was significantly different. In the transient transfection
model, the protein is expressed rapidly and at very high
levels, which likely results in the more amorphous appear-
ance of the aggregates, as has been shown by others
(Hackam et al., 1998). In the stable cells, expression of
N-Q82 resulted in the formation of very well-defined ag-
gregates, which is likely due to the fact that expression is
more controlled in the stably transfected cells, and hence
the proteins can organize into more well-defined struc-
tures (Lunkes and Mandel, 1998).
In conclusion, the results of the present study demon-
strate that tTG associates with wild-type, but not mutant,
truncated huntingtin; however, tTG does not modify the
huntingtin, either wild-type or mutant. Further, tTG is to-
tally excluded from the inclusions in the mutant truncated
huntingtin-expressing cells, and mutant huntingtin aggre-
gates form in the absence of tTG. These findings clearly
demonstrate that tTG is not essential for the formation of
huntingtin aggregates in HD brain.
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